Pulmonx Corp. (LUNG)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1127537 · fiscal year ends in Dec
Closing price $3.00 on 30 Oct 2026; 52-week range $1.17 to $3.16.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $87.4M
- Revenue growth
- -3.4%
- Net income, last twelve months
- -$48.1M
- Earnings per share
- -$1.16
- Gross margin
- 77.1%
- Operating margin
- -53.0%
- Net margin
- -55.0%
- Free cash flow
- -$30.7M
- Return on equity
- -122.8%
- Market value
- $128.8M
- Cash
- $55.8M
- Debt
- $37.5M
- Debt to equity
- 0.96
- Shares outstanding
- 42.9M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $90.5M | -$53.7M | -$54.0M | -$1.33 | -$32.8M | 10-K filed 10 Mar 2026 |
| FY2024 | 31 Dec 2024 | $83.8M | -$57.7M | -$56.4M | -$1.44 | -$33.0M | 10-K filed 25 Feb 2025 |
| FY2023 | 31 Dec 2023 | $68.7M | -$61.9M | -$60.8M | -$1.60 | -$38.4M | 10-K filed 27 Feb 2024 |
| FY2022 | 31 Dec 2022 | $53.7M | -$58.6M | -$58.9M | -$1.59 | -$46.4M | 10-K filed 1 Mar 2023 |
| FY2021 | 31 Dec 2021 | $48.4M | -$47.3M | -$48.7M | -$1.35 | -$45.1M | 10-K filed 1 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $22.8M | -$10.1M | -$0.24 |
| Q1 FY2026 | 31 Mar 2026 | $20.6M | -$13.7M | -$0.33 |
| Q4 FY2025 | 31 Dec 2025 | $22.6M | -$10.4M | -$0.25 |
| Q3 FY2025 | 30 Sep 2025 | $21.5M | -$14.0M | -$0.34 |
| Q2 FY2025 | 30 Jun 2025 | $23.9M | -$15.2M | -$0.38 |
| Q1 FY2025 | 31 Mar 2025 | $22.5M | -$14.4M | -$0.36 |
| Q4 FY2024 | 31 Dec 2024 | $23.8M | -$13.2M | -$0.33 |
| Q3 FY2024 | 30 Sep 2024 | $20.4M | -$14.1M | -$0.36 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| United States | $57.0M | 63.0% |
| Europe, Middle-East and Africa (“EMEA”) | $27.0M | 29.8% |
| Asia Pacific | $6.2M | 6.9% |
| Other International | $260.0K | 0.3% |
Company events
The newest 8-K filings of 41 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 27 Oct 2026 | 8-K | Results | 2.02, 9.01 |
| 29 Jul 2026 | 8-K | Results | 2.02 |
| 4 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 29 Apr 2026 | 8-K | Results | 2.02 |
| 5 Mar 2026 | 8-K | Material agreement, Agreement ended, New debt, Share sale | 1.01, 1.02, 2.03, 3.02, 9.01 |
| 4 Mar 2026 | 8-K | Results | 2.02 |
| 12 Nov 2025 | 8-K | Results | 2.02 |
| 27 Oct 2025 | 8-K | Results, Leadership change | 2.02, 5.02, 9.01 |
| 30 Jul 2025 | 8-K | Results | 2.02 |
| 23 May 2025 | 8-K | Shareholder vote | 5.07 |
| 30 Apr 2025 | 8-K | Results | 2.02 |
| 19 Feb 2025 | 8-K | Results | 2.02 |
Every filing
The newest filings with the SEC of 138 held.
| Filed | Form | Period |
|---|---|---|
| 27 Oct 2026 | 8-K | 27 Oct 2026 |
| 4 Aug 2026 | 10-Q | 30 Jun 2026 |
| 29 Jul 2026 | 8-K | 29 Jul 2026 |
| 4 Jun 2026 | 8-K | 4 Jun 2026 |
| 19 May 2026 | SD | – |
| 4 May 2026 | 10-Q | 31 Mar 2026 |
| 29 Apr 2026 | 8-K | 29 Apr 2026 |
| 22 Apr 2026 | ARS | 31 Dec 2025 |
| 22 Apr 2026 | DEFA14A | – |
| 22 Apr 2026 | DEF 14A | 4 Jun 2026 |
| 10 Mar 2026 | S-8 | – |
| 10 Mar 2026 | 10-K | 31 Dec 2025 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 1 Sep 2026 | French Glendon E. Iii, President and CEO | Sale outside a trading plan | 4,098 | $2.26 | $9.3K | 1,175,720 | 3 Sep 2026 |
| 1 Sep 2026 | French Glendon E. Iii, President and CEO | Sale outside a trading plan | 37,784 | $2.26 | $85.4K | 1,137,936 | 3 Sep 2026 |
| 1 Sep 2026 | Radhakrishnan Srikanth, Chief Science & Techn. Officer | Sale outside a trading plan | 2,643 | $2.26 | $6.0K | 328,596 | 3 Sep 2026 |
| 1 Sep 2026 | Radhakrishnan Srikanth, Chief Science & Techn. Officer | Sale outside a trading plan | 2,121 | $2.26 | $4.8K | 326,475 | 3 Sep 2026 |
| 1 Sep 2026 | Radhakrishnan Srikanth, Chief Science & Techn. Officer | Sale outside a trading plan | 3,618 | $2.26 | $8.2K | 322,857 | 3 Sep 2026 |
| 1 Sep 2026 | Radhakrishnan Srikanth, Chief Science & Techn. Officer | Sale outside a trading plan | 5,863 | $2.26 | $13.3K | 316,994 | 3 Sep 2026 |
| 1 Sep 2026 | Lehman David Aaron, General Counsel | Sale outside a trading plan | 3,807 | $2.26 | $8.6K | 372,354 | 3 Sep 2026 |
| 1 Sep 2026 | Lehman David Aaron, General Counsel | Sale outside a trading plan | 2,224 | $2.26 | $5.0K | 370,130 | 3 Sep 2026 |
| 1 Sep 2026 | Lehman David Aaron, General Counsel | Sale outside a trading plan | 3,476 | $2.26 | $7.9K | 366,654 | 3 Sep 2026 |
| 1 Sep 2026 | Lehman David Aaron, General Counsel | Sale outside a trading plan | 4,827 | $2.26 | $10.9K | 361,827 | 3 Sep 2026 |
| 1 Sep 2026 | Rose Geoffrey Beran, Chief Commercial Officer | Sale outside a trading plan | 2,213 | $2.26 | $5.0K | 455,498 | 3 Sep 2026 |
| 1 Sep 2026 | Rose Geoffrey Beran, Chief Commercial Officer | Sale outside a trading plan | 2,390 | $2.26 | $5.4K | 453,108 | 3 Sep 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 22 Jan 2026 | STEVEN WILLIAMSON, Officer, Director | 48,892 | $95.3K | 22 Jan 2026 |
| 15 Jan 2026 | STEVEN WILLIAMSON, Officer, Director | 15,892 | $31.0K | 15 Jan 2026 |
| 14 Jan 2026 | STEVEN WILLIAMSON, Officer, Director | 31,082 | $62.1K | 14 Jan 2026 |
| 8 Dec 2025 | DANIEL P FLORIN, Director | 23,321 | $46.4K | 8 Dec 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 13 Aug 2026 | Morgan Stanley | 13G amended | 6.9% | 2.9M |
| 29 Jul 2026 | BlackRock, Inc. | 13G amended | 1.8% | 765.7K |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 9 Mar 2026 | Soleus Capital Master Fund, L.P. | 13G | 6.5% | 2.7M |
| 13 Nov 2025 | PRIMECAP MANAGEMENT CO/CA/ | 13G amended | 12.16% | 5.0M |
| 7 Nov 2025 | FMR LLC | 13G amended | 0.2% | 70.8K |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 698.6K | -12.97% | 2.54 |
| 30 Sep 2026 | 802.7K | -5.32% | 3.2 |
| 15 Sep 2026 | 847.8K | -13.15% | 2.51 |
| 31 Aug 2026 | 976.2K | -8.47% | 2.58 |
| 14 Aug 2026 | 1.1M | +0.6% | 1.18 |
| 31 Jul 2026 | 1.1M | +0.37% | 1.45 |
| 15 Jul 2026 | 1.1M | -8.06% | 4.64 |
| 30 Jun 2026 | 1.1M | -49.24% | 1.33 |
Funds that hold it
From each fund's latest Form 13F.
132 funds held it at 30 Jun 2026: 55 added and 35 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Primecap Management Co. | 4,612,331 | $6.0M | -112,660 |
| Morgan Stanley | 2,922,921 | $3.8M | -1,070,641 |
| Soleus Capital Management, L.P. | 2,788,323 | $3.6M | 0 |
| Vanguard Capital Management LLC | 1,630,219 | $2.1M | -4,045 |
| ExodusPoint Capital Management, LP | 1,223,555 | $1.6M | -720,279 |
| Almitas Capital LLC | 1,064,202 | $1.4M | +1,064,202 |
| BlackRock, Inc. | 882,490 | $1.1M | -1,779,117 |
| Stonepine Capital Management, LLC | 815,436 | $1.1M | +47,148 |
| Jane Street Group, LLC | 758,231 | $985.7K | +624,961 |
| Braidwell LP | 752,541 | $978.3K | 0 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B